Efficacy and safety of pembrolizumab as first-line therapy in advanced non-small cell lung cancer with at least 50% PD-L1 positivity: a multicenter retrospective cohort study (HOPE-001)
暂无分享,去创建一个
J. Uchida | Hidekazu Suzuki | Y. Fukuda | K. Hirano | T. Hirashima | T. Yokoyama | M. Tamiya | A. Tamiya | T. Kumagai | D. Fujimoto | S. Hara | Nobuhiko Sawa | Y. Taniguchi | M. Kanazu | M. Morita | K. Hosoya | H. Matsumoto | Ryota Kominami | Y. Kinoshita | N. Sawa